This matters because many people asking the question yet? are reacting to news that sounds broader than the current reality
13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility In a 2-year carcinogenicity study in CD-1 mice, subcutaneous doses of 0.3, 1 and 3 mg/kg/day [2-, 11-, and 30-fold the maximum recommended human dose (MRHD) of 2 mg/week, based on AUC] were administered to the males, and 0.1, 0.3 and 1 mg/kg/day (1-, 2-, and 7-fold MRHD) were administered to the females
It is taken weekly, but some patients may experience mild gastrointestinal side effects such as nausea, vomiting, and diarrhea
This is a head-to-head comparison, and [orforglipron] is certainly quite effective. According to the treatment-regimen estimand, weight loss at 1 year was 6.1% with orforglipron 12 mg, 8.2% with orforglipron 36 mg, 3.9% with oral semaglutide 7 mg and 5.3% with oral semaglutide 14 mg
Wegovy supports appetite control via GLP-1, but metabolism naturally adjusts during weight reduction